Dear Researcher,
The coronavirus outbreak has now been labelled a pandemic by WHO. There are currently no antiviral drugs licensed by the FDA to treat patients from COVID-19. Remdesivir was reported to have in-vitro activity against SARS-CoV-2 and is now in the clinical trial phase. Researchers across the globe are working on the development of candidate vaccines and therapeutics for an effective antiviral molecule. In this newsletter, we are showcasing some of our product categories which are helpful in the R&D of antiviral therapies and can be an essential tool to aid the researchers.

We hope that you find this newsletter to be a valuable source of information.

Bromodomain Inhibitors
	I-BET 151 Catalog No: I120050 Part of a novel series of quinoline isoxazole BET family bromodomain inhibitors, a family of four proteins that selectively bind to acetylated lysine residues in histone   Learn more
Remdesivir Metabolite
	Remdesivir Carboxylic Acid Catalog No: R530520 A metabolite of Remdesivir (CAS#:1809249-37-3); small molecule GS-​5734 with therapeutic efficacy against Ebola virus in rhesus monkeys.   Learn more
Abl Kinase Inhibitors
	GNF 2 Catalog No: B820020 An inhibitor of c-Abl and Bcr-abl activity Primarily used for Phosphorylation & Dephosphorylation applications.   Learn more
RdRp Inhibitors
	BCX 4430 Catalog No: B119190 An adenosine analog developed by BioCryst Pharma. Potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease.   Learn more
OSBP Inhibitors
	Itraconazole Catalog No: I937500 Itraconazole is an antifungal and inhibitor of hedgehog signalling   Learn more
Endosomal pH Regulators
	SN 7618 Catalog No: C379965 Substrate for MRP in multidrug-resistant cell line and inhibits photoaffinity labelling of MRP by quinoline-based photoactive drug IAAQ.   Learn more